Q-omics provides the consensus-scored THADA profile across patient tissues and cancer cell-line models. THADA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, THADA is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, THADA protein abundance shows 31,438 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where THADA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THADA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THADA survival associations across molecular data types. THADA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THADA RNA expression–survival associations across cancer types. High THADA expression shows unfavorable associations in ACC, MESO, UVM, LGG and COAD, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for THADA RNA expression.
This table summarizes THADA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THADA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THADA shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and COAD. The HNSC box plot shows higher THADA RNA expression in tumor versus normal tissue (log2 FC = +0.674, t-test p < 0.001).
This table shows molecular features associated with THADA in patient tissues and cancer cell lines. In patient samples, THADA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, THADA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
